Following amendments were made: Information on the recent European Society of Cardiology (ESC) 2014 guidelines was added. •Clarification that the subset of subjects who might receive MB-102 and monitored by ORFM would be from selected sites in the USA. •Clarification on use of NSAIDs and excluded medication. •Clarification of SAE reporting, laboratory AE evaluation, and blood sampling at Follow-up 1. •Critical study events were more fully defined. •Clarification of hydration requirements and the use of intravenous (i.v.) hydration. •Clarification of procedures at screening and baseline, including timing of visits and signing of informed consent. •Definition of the per-protocol set was updated. •Minor typographical errors were corrected.

•Acceptable methods of contraception were further clarified to include acceptable, but not highly effective, birth control methods in line with guidelines and informed consent. •Period of metformin discontinuation prior to the Baseline Visit was increased from 24 hours to 48 hours in line with core safety information. •Thyroid-stimulating hormone (TSH) was added to the Screening laboratory evaluation.

•Potentially eligible subjects could enter this study any time during their post-Endovascular Aneurysm Repair (EVAR) follow-up, once they had passed the first imaging examination (commonly scheduled 1 month after the index EVAR), and if no complications, such as endoleaks, had been detected. Consequently, assessment for eligibility could happen years after the index EVAR, when documentation of the first imaging exam might not be available, despite subsequent follow-up examination(s) providing sufficient assurance on the stable post- EVAR status of such subjects. The changes in inclusion criteria and exclusion criterion aim to allow enrolment of otherwise eligible post-EVAR subjects in cases where documentation and evidence on the first month imaging examination were not available. The requirement for stable post-EVAR conditions (no endoleak, no clinically meaningful EVAR-related complication) was unchanged, so the characteristics of the subject population remained unchanged. •The screening period was increased from 7 days to 14 days for logistical reasons. •Recent literature reference was added. •A definition of the end of the study was added. •Clarification that randomization was in a 1:1 ratio. •Text added to clarify that the use of N-acetylcysteine was discouraged for the purpose of preventing AKI. •The period of time after which the Sponsor reserves the right to discontinue participation of a study center at which no subjects had been enrolled wasincreased from within 3 months to within 6 months of initiation. •Clarification that ‘personnel who were trained in the acute management of anaphylaxis and other emergencies and who have access to appropriate clinical supplies must be immediately available for 30 minutes after dosing’ was added.